Importing and exporting biological samples: Dos and don’ts
To ensure that your drug program’s timeline stays on track, it is crucial to follow the strict guidelines for importing and exporting biological samples. Too often, there are several mistakes with execution that could have been avoided with proper planning, coordination, and communication. These errors not only lead to frustration but also can result in:
- Costly delays
- Project rework
- Logistic challenges
- Lost, delayed, or damaged samples
- Handling mishaps
Discover the 5 best practices and mistakes to avoid when navigating the import and export of biological samples.
Build a bioanalytical strategy that will ensure speed and agility
In order to build a robust bioanalytical strategy for your drug discovery program, it’s crucial to collaborate with a partner who possesses both industry expertise and a track record of operational success.
Aliri by the numbers:
- 48-hour turnarounds in discover
- 150 biological fluids & tissues
- 1 million samples analyzed
Our team of seasoned scientists, industry experts, program managers, and quality specialists can help you develop a successful bioanalytical strategy that will maximize the growth of your drug discovery investments. Work with us to gain access to a robust suite of mass spectrometry platforms, achieve quality data to quickly file your IND, NDA and CTA, and forecast potential roadblocks that may cause delays in your project’s timeline.
Download our factsheet to explore our offerings, platforms, compounds, regulations and more.
Validating the efficacy of a compound with spatial imaging
With the ever-changing drug development landscape, pharma and biotech companies have the challenging task to quickly and efficiently generate quality and unique data to file an IND. Spatial bioanalysis is a unique solution that can help you achieve this goal, while also enabling strategic and optimized decision making throughout your process.
Download this spatial bioanalysis white paper to gain insights from industry expert, Corinne Ramos, PhD. Discussion points include:
- Precision medicine development and added value
- Disease heterogeneity: Why is it? Why is it important? How do we visualize it?
Target discovery and development of composite biomarkers
Streamlining the Importing and Exporting of Biological Samples
With the evolving requirements of importing and exporting biological samples, there is a heightened priority to proactively plan, execute, and coordinate procedures. Streamlining this process can help improve logistics, ensure timely execution, and increase workflow efficiencies. Despite the complexity, importing and exporting biological samples can become a seamless and predictable phase in research and development, especially when partnering with the right bioanalytical partner.
Download this white paper to learn from industry expert Mark Vann.
Non-proprietary Assays
There are many factors to consider when choosing a bioanalysis partner for your project. One of which should be finding a company with the scientific expertise and resources you need to move forward with speed, accuracy, and certainty. One of those resources being a large assortment of assays.
Aliri has over 1500 non-proprietary assays that allow us to measure a wide variety of compounds using our advanced technology. Our expertise will advance your molecule with speed and agility!
Our species matrices include:
- Human Plasma
- Human Serum
- Human Whole Blood
- Whole Blood
- Human Dried Blood Spot
- Human Urine
Most common Assays:
- Budesonide
- Bupropion, Hydroxybupropion
- Diclofenac
- Naloxone
- Naltrexone/ Naltrexol
- Pregabalin
- Riluzole
- Rosuvastatin
- Rosuvastatin/ Desmethyl Rosuvastatin/ Rosuvastatine Lactone
- Tenofovir
- Tiotropium
Download our latest comprehensive list of non-proprietary assays available for you.